Sylvie Freeman

8.8k total citations · 2 hit papers
73 papers, 3.3k citations indexed

About

Sylvie Freeman is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Sylvie Freeman has authored 73 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Hematology, 31 papers in Molecular Biology and 20 papers in Genetics. Recurrent topics in Sylvie Freeman's work include Acute Myeloid Leukemia Research (55 papers), Acute Lymphoblastic Leukemia research (17 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers). Sylvie Freeman is often cited by papers focused on Acute Myeloid Leukemia Research (55 papers), Acute Lymphoblastic Leukemia research (17 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers). Sylvie Freeman collaborates with scholars based in United Kingdom, United States and Denmark. Sylvie Freeman's co-authors include David Grimwade, Paul R. Crocker, Sørge Kelm, Nigel H. Russell, Alan K. Burnett, Robert K. Hills, Farhad Ravandi, Roland B. Walter, Andrew H. Wei and Courtney D. DiNardo and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Sylvie Freeman

70 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

2020 207 citations Nicholas J. Short, Shouhao Zhou et al. profile →
Acute myeloid leukaemia

2023 193 citations Sylvie Freeman, Andrew H. Wei et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sylvie Freeman United Kingdom	27	2.0k	1.5k	840	589	535	73	3.3k
Geoffrey L. Uy United States	32	2.9k 1.5×	1.6k 1.1×	900 1.1×	751 1.3×	1.5k 2.9×	214	4.6k
Brian Van Ness United States	35	2.4k 1.2×	2.2k 1.4×	569 0.7×	209 0.4×	1.3k 2.3×	83	3.7k
ID Bernstein United States	25	1.8k 0.9×	1.2k 0.8×	1.2k 1.4×	241 0.4×	677 1.3×	51	3.4k
Valeria Visconte United States	29	1.8k 0.9×	1.4k 0.9×	756 0.9×	162 0.3×	406 0.8×	181	3.2k
Michael H. Tomasson United States	32	1.8k 0.9×	1.6k 1.1×	486 0.6×	164 0.3×	1.3k 2.3×	116	3.5k
A Strife United States	30	1.3k 0.7×	1.2k 0.8×	501 0.6×	274 0.5×	544 1.0×	59	2.7k
Marc Loriaux United States	34	2.2k 1.1×	2.0k 1.3×	678 0.8×	316 0.5×	808 1.5×	98	4.5k
Michael Morgan Germany	32	2.2k 1.1×	2.5k 1.6×	1.0k 1.2×	503 0.9×	1.5k 2.8×	106	5.0k
Catherine Pellat‐Deceunynck France	36	1.5k 0.8×	1.9k 1.2×	1.3k 1.5×	87 0.1×	1.2k 2.3×	98	3.7k
SD Lyman United States	26	1.4k 0.7×	904 0.6×	1.4k 1.7×	127 0.2×	560 1.0×	33	3.1k

Countries citing papers authored by Sylvie Freeman

Since Specialization

Citations

This map shows the geographic impact of Sylvie Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Freeman more than expected).

Fields of papers citing papers by Sylvie Freeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvie Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Freeman. The network helps show where Sylvie Freeman may publish in the future.

Co-authorship network of co-authors of Sylvie Freeman

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvie Freeman. A scholar is included among the top collaborators of Sylvie Freeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvie Freeman. Sylvie Freeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Russell, Nigel H., Jad Othman, Oliver Cumming, et al.. (2025). Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 -mutated AML. Blood Advances. 9(24). 6455–6466.

Gui, Gege, Christophe Roumier, Georgia Andrew, et al.. (2024). Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance. Leukemia. 38(8). 1667–1673. 9 indexed citations

Liao, Aiyin, Naeem Khan, Sylvie Freeman, et al.. (2024). Potent and Effective Targeting of AML with ‘Off-the-Shelf’ Engineered CD45-Targeting CAR T-Cells. Blood. 144(Supplement 1). 2024–2024. 2 indexed citations

Othman, Jad, Nicola Potter, Adam Ivey, et al.. (2024). Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 143(19). 1931–1936. 33 indexed citations

Loke, Justin, Aimee Jackson, Shamyla Siddique, et al.. (2023). Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS. Blood Advances. 7(14). 3666–3676. 21 indexed citations

Hokland, Peter, Sylvie Freeman, Bjørn Tore Gjertsen, et al.. (2023). AML in the elderly—A global view. British Journal of Haematology. 203(5). 760–773. 2 indexed citations

Ravandi, Farhad, Jacqueline Cloos, Francesco Buccisano, et al.. (2023). Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel. American Journal of Hematology. 98(12). 1847–1855. 10 indexed citations

Schulz, Eduard, Peter D. Aplan, Sylvie Freeman, & Steven Z. Pavletic. (2023). Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes. Blood Advances. 7(16). 4381–4394. 7 indexed citations

Kumar, Kailash, Sylvie Freeman, Maria Melchior, & Bian Liu. (2023). 9939 Management of Complex Tubo-Ovarian Abscesses: A Stepwise Surgical Approach. Journal of Minimally Invasive Gynecology. 30(11). S94–S94.

10.

Russell, Nigel H., Jad Othman, Richard Dillon, et al.. (2023). S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL. HemaSphere. 7(S3). e252478c–e252478c. 1 indexed citations

11.

Short, Nicholas J., Chenqi Fu, Donald A. Berry, et al.. (2022). Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 36(12). 2817–2826. 20 indexed citations

12.

Mehta, Priyanka, Nick Telford, Richard Dillon, et al.. (2022). Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. British Journal of Haematology. 200(2). 150–159. 4 indexed citations

13.

Krämer, Michael, Christian Thiede, Stefan W. Krause, et al.. (2022). Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. Leukemia. 36(9). 2208–2217. 12 indexed citations

14.

Burnett, Alan K., Nigel H. Russell, Robert K. Hills, et al.. (2020). Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. Journal of Clinical Oncology. 39(8). 890–901. 19 indexed citations

15.

Milne, Paul, Charlotte S. Wilhelm-Benartzi, Michael R. Grunwald, et al.. (2019). Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances. 3(20). 3052–3061. 17 indexed citations

16.

Vyas, Paresh, Charlotte Bradbury, Peter Richardson, et al.. (2013). COMBINED ANALYSES OF ROS, CELL CYCLE AND IMMUNOPHENOTYPE SHOWS THAT NORMAL HEMATOPOIETIC PROGENITOR SUBSETS HAVE A DIFFERENTIAL ROS PROFILE THAT IS LOST IN ACUTE MYELOID LEUKEMIA. Haematologica. 98. 12–12. 1 indexed citations

17.

Picone, Cristina, Laura Vanelli, Luca Malcovati, et al.. (2011). MULTICENTRE VALIDATION OF A REPRODUCIBLE FLOW CYTOMETRIC SCORE FOR THE DIAGNOSIS OF LOWRISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A EUROPEAN LeukemiaNET STUDY. Cytometry Part A. 1051–1052. 1 indexed citations

18.

Jenkins, Peter & Sylvie Freeman. (2008). Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Annals of Oncology. 20(1). 34–40. 49 indexed citations

19.

Erickson‐Miller, Connie L., Sylvie Freeman, Christopher B. Hopson, et al.. (2003). Characterization of Siglec-5 (CD170) expression and functional activity of anti–Siglec-5 antibodies on human phagocytes. Experimental Hematology. 31(5). 382–388. 29 indexed citations

20.

Crocker, Paul R., Sylvie Freeman, Siamon Gordon, & Sørge Kelm. (1995). Sialoadhesin binds preferentially to cells of the granulocytic lineage.. Journal of Clinical Investigation. 95(2). 635–643. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact